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Deep brain stimulation (DBS) of the periaqueductal gray (PAG) is used in the treatment of severe re-
fractory neuropathic pain. We tested the hypothesis that DBS releases endogenous opioids to exert its
analgesic effect using [11C]diprenorphine (DPN) positron emission tomography (PET). Patients with de-
afferentation pain (phantom limb pain or Anaesthesia Dolorosa (n¼5)) who obtained long-lasting an-
algesic beneﬁt from DBS were recruited. [11C]DPN and [15O]water PET scanning was performed in con-
secutive sessions; ﬁrst without, and then with PAG stimulation. The regional cerebral tracer distribution
and kinetics were quantiﬁed for the whole brain and brainstem. Analysis was performed on a voxel-wise
basis using statistical parametric mapping (SPM) and also within brainstem regions of interest and
correlated to the DBS-induced improvement in pain score and mood. Brain-wide analysis identiﬁed a
single cluster of reduced [11C]DPN binding (15.5% reduction) in the caudal, dorsal PAG following DBS
from effective electrodes located in rostral dorsal/lateral PAG. There was no evidence for an accom-
panying focal change in blood ﬂow within the PAG. No correlation was found between the change in PAG
[11C]DPN binding and the analgesic effect or the effect on mood (POMSSV) of DBS. The analgesic effect of
DBS in these subjects was not altered by systemic administration of the opioid antagonist naloxone
(400 ug). These ﬁndings indicate that DBS of the PAG does indeed release endogenous opioid peptides
focally within the midbrain of these neuropathic pain patients but we are unable to further resolve the
question of whether this release is responsible for the observed analgesic beneﬁt.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The mechanisms of action of deep brain stimulation (DBS) for all
indications are under active investigation (Gradinaru et al., 2009;
Kringelbach et al., 2007; Okun, 2014) and it is evident that different
neural substrates are modulated depending on implantation target,
stimulation parameters and disease aetiology. DBS of the periaque-
ductal gray (PAG) has been used for the treatment of pain for over
ﬁfty years (Duncan et al., 1991) and continues to ﬁnd use for re-
fractory syndromes such as de-afferentation pain (Bittar et al., 2005).Inc. This is an open access article
norphine; PAG, periaqueductal
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i.org/10.1016/j.neuroimage.It was introduced following the striking demonstration of electro-
analgesia obtained from stimulation of the midbrain in rats (Rey-
nolds, 1969). Further studies localised this action to the PAG, which
was found to engage a descending inhibitory system to alter spinal
processing of nociceptive inputs (Mayer and Liebeskind, 1974; Mayer
et al., 1971).
This electro-analgesic action of PAG DBS in animal models was
reversible with the opioid antagonist naloxone (Akil et al., 1976) –
consistent with the high density of opioid receptor binding in the
PAG (Kuhar et al., 1973). Similarly, early studies of PAG DBS in pa-
tients reported analgesic actions that were reversible with opioid
antagonists (Hosobuchi et al., 1977). However, it is now apparent
from animal studies that there are both opioidergic and non-
opioidergic mechanisms of PAG analgesia (Bandler and Shipley,
1994; Heinricher et al., 2009). Similarly, carefully controlled and
blinded studies in patients showed PAG electro-analgesia is not fully
blocked with naloxone and does not show cross-tolerance to sys-
temically administered opioids (Duncan et al., 1991; Young andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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DBS have previously failed trials of systemic opioids. Therefore
there is an unresolved question about the neurochemical basis of
the beneﬁcial effects of DBS of the PAG.
We have sought to address the question of mechanism of an-
algesic action using an opioid radioligand positron emission tomo-
graphy (PET) strategy to study patients with implanted DBS systems
for intractable de-afferentation pain. Previous opioid PET studies in
healthy subjects have demonstrated that acute painful stimuli (Zu-
bieta et al., 2001) decrease opioid receptor availability in pain pro-
cessing areas of the brain. This is due to the release of endogenous
opioids that compete with the radio-ligand. We have employed an
analogous opioid PET approach using [11C]-diprenorphine ([11C]DPN)
to test whether acute DBS of the PAG causes release of endoge-
nous opioid peptides with a particular focus on the mid-brain and
brainstem.2. Materials and methods
2.1. Patients and study design
After approval from the NHS ethical committee (Ref. 12/SW/
0255), North Bristol NHS Trust research and development (Ref.
2875) and Administration of Radioactive Substances Advisory
Committee (Ref. 595/3586/29156 – Karl Herholz), the study was
registered with the National Institute for Health Research Com-
prehensive Clinical Research Network (Ref. 13580).
We performed a sequential PET imaging study to examine the
effect of DBS on opioid radiotracer binding to all opioid receptor
subtypes (using [11C]DPN, a non-selective opioid receptor an-
tagonist) and on blood ﬂow (using [15O]water) in the brain and
brainstem. The study tested the primary hypothesis that activation
of DBS releases endogenous opioid at the site of stimulation in the
PAG. The secondary hypotheses were that DBS would also release
opioid peptides in brainstem regions believed to play a role in pain
processing and modulation. We also sought correlations between
regional opioid release in these areas and analgesic beneﬁt / im-
provement in mood.
We planned to recruit ﬁve subjects from an existing cohort of
patients (n¼9) being treated with DBS for refractory de-affer-
entation pain. These patients had DBS systems already implanted
following funding approval from the NHS exceptional clinical need
panel, according to the criterion of lack of response to optimal
conventional treatment and no sign of spontaneous recovery/im-
provement after two years following the initial referral to a sec-
ondary care pain service. All patients had electrodes (Medtronic
3387) implanted into the PAG on the contralateral side to their
pain using a magnetic resonance imaging–directed method of
targeting (Patel et al., 2007). Several subjects also had electrodes
implanted into the centre median-parafasicular (CM-Pf) complex
or the ventro-posterolateral nucleus of the thalamus. For further
details of the time-course of the response to treatment of the
Anaesthesia Dolorosa patients see Sims-Williams et al. (2016).
In designing the study we aimed to detect opioid release when
the DBS system was activated and anticipated that this would be a
different biological mechanism from the change seen in transi-
tioning from DBS on to off where the process would be a dis-
sociation of opioid from receptors and peptide degradation (hence
with different kinetics). We employed kinetic modelling based on
the arterial plasma [11C]DPN to maximise our sensitivity to detect
changes in opioid binding. For ethical reasons we were mandated
to minimise the number of cannulations (particularly relevant for
our amputees) so performed the two scan sessions on the same
day (allowing a single cannula). We performed sequential
[11C]DPN and [15O]water scans with the ﬁrst scan session withPlease cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.stimulator off followed by identical scans with stimulator on
(protocol timeline in Fig. 1B). Subjects had 44 h interval between
the sets of radiotracer injections to allow 45 [11C] half-lives
(T1/2 20 min) to minimise carry over effects due to radioactivity
contamination of the second scan by the ﬁrst scan dose. Study
blinding was deemed unfeasible as all of our participants were
aware of their stimulator being switched off because their pain
returned.
Written informed consent was obtained from all subjects in
accordance with the declaration of Helsinki. Eight subjects (three
with Anaesthesia Dolorosa and ﬁve with Phantom Limb Pain) were
screened for inclusion (criteria in Table 1). Two subjects were
subsequently excluded; one due to poor acute temporal response
to DBS activation/inactivation, the other could not tolerate sti-
mulation withdrawal for sufﬁcient time to allow PET scanning
(3 h). One subject withdrew from the study prior to PET scan-
ning. The ﬁve enroled subjects, three with Anaesthesia Dolorosa
and two with Phantom Limb Pain (Table 2, Inline Supplementary
Clinical Vignettes), had their DBS stimulation settings reviewed
and optimised where necessary prior to scanning (see Supple-
mentary Table 1 for details).
An initial supervised trial “off stimulation” was performed in
the clinic to introduce the pain and mood scoring scales. Subjects
then completed a home diary, monitoring the effect of stimulation
on visual analogue pain scores (VAS, 0–10) and mood (Proﬁle of
Mood State Shortened Version questionnaire (POMSsv) (Shacham,
1983)). Each subject recorded three baseline VAS pain scores and a
single POMSsv assessment before switching off their PAG DBS and
recording their pain score at intervals (10, 20, 30, 60, 90, 120, 150
and 180 min). After 120 min, subjects completed the POMSsv
questionnaire before switching their DBS back on; repeating the
VAS and POMSsv rating at the same intervals.
2.2. PET scanning
Subjects attended the University of Manchester Wolfson Mo-
lecular Imaging Centre for PET scanning. Female subjects com-
pleted a screening questionnaire to exclude the possibility of
pregnancy. Prior to scanning, and under local anaesthesia, an 18-
gauge cannula was inserted into the antecubital vein for the in-
jection of the radiotracer and a 22-gauge arterial cannula was in-
serted into the distal radial artery for blood sampling. For the
phantom limb subjects the arterial and venous cannulae were si-
ted in the preserved arm – for all other subjects they were inserted
on opposite sides.
A High Resolution Research Tomograph (Siemens, Knoxville, TN)
camera (de Jong et al., 2007) together with both [15O]water and
[11C]DPN tracers were used to measure radiotracer delivery and
opiate receptor binding, ﬁrst with PAG DBS off and subsequently
repeated with PAG DBS active. The scanning environment was kept
consistent across subjects and between sessions. Subjects were po-
sitioned with their head well within the 25 cm axial ﬁeld of view of
the PET camera, which enabled simultaneous brainstem and brain
measurements. Accurate repeat positioning between the two scan-
ning periods was enabled by recording table height and translation
as well as laser cross hair and facial contour alignment on a video
monitor. Any head movement during scanning was monitored using
an optical neuro-navigation system (Polaris VICRA
s
). In 4/5 subjects
all radiotracer injections were done on the same day during two
scanning periods and in one subject the second [11C]DPN injection
occurred on the following day (due to a radio-synthesis failure for the
planned second scan) with the same protocol timings. Two subjects
kept CM-Pf stimulation on throughout the PET scanning protocol to
maintain control of their symptoms (h00634 and h00635). CM-Pf
stimulation was switched off for a 12 h period prior to PET scan-
ning in two subjects (h00631 and h00683) and was then left offlation of the periaqueductal gray releases endogenous opioids in
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Table 1
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
 Implanted PAG DBS system for de-af-
ferentation pain
 Pre-existing structural brain
abnormality
 Maintained improvement in pain score
of 430%
 Inability to tolerate 3 h without DBS
 Presence of clear temporal analgesic
response to DBS
 Contraindication to PET scanning
 Able to provide informed consent  Unsuitability for arterial cannulation
 Able to comply with all testing
protocols
 Unstable analgesic medication
 Age o30 years
 Pregnancy
Fig. 1. Acute analgesic effects of DBS and change in [11C]DPN binding. (A) Change in pain scores with DBS stimulation assessed during home trial. The analgesic effect of
stimulation was almost completely lost 60 min after inactivation of DBS (pain VAS increased from 2.570.8 to 4.471.3, po0.05, n¼5) to reach a plateau level of pain that
continued for more than two hours. On re-commencing PAG stimulation the analgesic effect was evident within 30 min (pain VAS reduced by 41% from 5.171.8 to 3.071.2)
and this analgesic action was maintained for the rest of the test period. (rm-ANOVA with Dunnett's posthoc tests, *,# – po0.05; **, ## – po0.01, ***,### – po0.001.).
(B) Timeline of the sequential [15O]water and [11C]DPN scans with the ﬁrst scanning session following 60 min after DBS was stopped and the second commencing 60 min
after DBS was reinstated. Shown alongside is a representative sagittal parametric image of the volume of distribution (VT) for [11C]DPN overlaid on T1-weighted MRI image
for a single subject (h00635) with DBS off. The image shows a characteristic distribution of the opioid ligand with high binding in the thalamus, midbrain and in several
cortical regions (such as prefrontal and cingulate) but low binding in the occipital cortex and the pontine nucleus.
H. Sims-Williams et al. / NeuroImage ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 3throughout the session; the remaining subject (h00636) did not have
a second functioning stimulator. Pain, mood and anxiety scores were
taken at baseline, after DBS was switched off/on (90 min prior to the
scan) and at 0, 30 and 90 min during each [11C]DPN scan.Table 2
Subject demographics.
Study ID Sex Age Pain syndrome
h00631 F 50 Anaesthesia Dolorosa
h00634 M 31 Anaesthesia Dolorosa
h00635 F 52 Anaesthesia Dolorosa
h00636 M 63 Phantom Limb Pain
h00683 M 50 Phantom Limb Pain
DBS – deep brain stimulation, PAG – Periaqueductal gray, CM-Pf centre median-parafas
VPL – ventral posterolateral nucleus of the thalamus.
Please cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.2.2.1. Scan data acquisition
Each of the two scanning sessions consisted of the same se-
quence of events. At the start of each session a Cesium-137
transmission scan was performed and used to correct the sub-
sequent scans for photon attenuation and scatter (Knoess et al.,
2004). This was followed by two separate sequential injections of
[15O]water (596 [517-639] MBq, median [range]) using an auto-
mated injection system (Radiowater Generator, Hidex Oy), fol-
lowed by an injection of [11C]DPN (radiochemical purity 495%,
507 [277–566] MBq, 2.5 [0.5–18.5] mg, median [range]) given in-
travenously over 20 s followed by a saline ﬂush. Following injec-
tion of [15O]water a period of at least 15 min elapsed before any
subsequent injection to allow for radioactive decay. PET data were
collected over the entire duration of the three injections until
90 min postinjection of [11C]DPN. The PAG DBS system was swit-
ched off 60 min prior to the ﬁrst [15O]water radiotracer injection
(90 min prior to [11C]DPN) for the initial session and turned back
on 4.5 h later and the sequence of radiotracer injections and scans
was repeated.Duration of DBS (months) Electrode side Target(s)
15 Left PAG, CM-Pf
7 Right PAG, CM-Pf
34 Right PAG, CM-Pf
60 Left PAG, VPL
64 Right PAG, CM-Pf
icular complex.
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Prior to scanning a 12 mL baseline blood sample was taken to
quality assure blood analytical measurements using [11C]DPN-spiked
blood. Continuous arterial blood sampling was started (5 mL min1)
immediately prior to each [15O]water and [11C]DPN injection and
continued until 6 (water) and 10 (DPN) minutes postinjection, with
continuous radioactivity measurements made using a bespoke Bis-
muth Germanate detector (Ranicar et al., 1991). For the [15O]water
injection discrete samples were taken at 4, 5 and 6 min postinjection
with whole blood radioactivity concentrations determined and used
to calibrate the continuous arterial blood measurements. For
[11C]DPN, discrete samples were also taken at 5, 7.5, 10, 15, 20, 30, 40,
50, 60, 75, and 90 min postinjection with whole blood and plasma
radioactivity concentrations determined. Blood radioactivity mea-
surement were made using a bespoke calibrated NaI well counter.
Additionally for the samples taken at 5, 10, 20, 30, 40, 60 and 75 min
the fractional activity of un-metabolised [11C]DPN in blood plasma
was determined with chemical separation performed using solid-
phase extraction followed by High Performance Liquid Chromato-
graphy and with radioactivity measurements of the eluent made
using a 10 well calibrated gamma counter (Wallac Wizard 1470,
Perkin Elmer). A total of 47 mL (water) and 160 mL (DPN) of blood
was withdrawn per radiotracer injection. From these measurements
(after full corrections for background, dead-time and sample volume)
input functions of [15O]water in arterial whole blood and [11C]DPN in
arterial blood plasma were determined and used in the subsequent
kinetic modelling.
2.2.3. Image reconstruction
Image reconstruction was performed using the HRRT user
community software implementation of a 3D re-projection algo-
rithm (3DRP) (Kinahan and Rogers, 1989) and ordered subset ex-
pectation maximisation algorithm (OSEM) (Hudson and Larkin,
1994). Dynamic image volumes were reconstructed using 3DRP to
measure changing radioactivity concentrations over a 6 min peri-
od following [15O]water administration with contiguous frame
durations of 60 s (background), 105 s, 610 s, 320 s and
630 s. Similarly following [11C]DPN administration, image vo-
lumes were reconstructed using 3DRP over a 90 min period with
contiguous frame durations of 60 s (background), 310 s, 730 s,
12120 s, 6300 s and 3600 s. This image data was used for
subsequent kinetic modelling. In addition, a single image volume
of the activity concentration over the 90 s period following
[15O]water injection was reconstructed using 3DRP. Likewise a
single image volume of the activity concentration during the
90 min period following [11C]DPN injection was reconstructed
using OSEM (16 subsets, 12 iterations) and using resolution mod-
elling (HRRT user community default kernel (Comtat et al., 2008)).
These later static images were used for the determination of
spatial processing parameters using SPM. In addition the 90 s
images following [15O]water injection were used to examine
changes in regional blood ﬂow. Corrections for photon attenuation,
scatter, detector dead-time, and different lines of response sensi-
tivities (normalisation correction) were applied for both sets of
reconstructions. The scan of one subject had signiﬁcant discrete
motion; therefore reconstruction with motion correction was used
which included motion based reframing of the data and correc-
tions for photon attenuation and scatter (Segobin et al., 2009).
2.3. Data analysis
2.3.1. Generation of parametric maps
Kinetic modelling was performed in order to generate parametric
images. For [15O]water data the dynamic images were ﬁrst convolved
with a 4 mm full width at half the maximum (FWHM) Gaussian
kernel with regional cerebral blood ﬂow (rCBF) values subsequentlyPlease cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.estimated using the generalised linear least-squares (GLLS) method
(Walker et al., 2012). For the [11C]DPN data, parametric images of the
rate of [11C]DPN delivery (K1) and steady state total volume of dis-
tribution (VT) were estimated using spectral analysis modelling
(Cunningham and Jones, 1993). The spectral analysis model was
constructed using 100 spectra logarithmically spaced from
2102 s1 to 1103 2 s1 together with and additional spectra
for blood volume which is similar to previously published methods
(Hammers et al., 2007), and ﬁtted using a non-negative linear least
squared algorithm (Lawson and Hanson, 1974). For both tracers glo-
bal delays between the blood and brain measurements were de-
termined using TAC data from a region over the entire PET camera
ﬁeld of view and repeatedly ﬁtting the models with different delays
and using a golden ratio line search algorithm. For [15O]water an
additional global dispersion of τ¼10 s was used (Iida et al., 1986). The
parametric images for both tracers were subsequently median ﬁl-
tered (3 iterations of 333 cubic kernel), as noise in the PET
images results in a skewed non-Gaussian distribution of the esti-
mated rate constants with a long high valued tail. In the case of
[11C]DPN the skewedness was exacerbated by the wide spectral
range as low as 1103  2 s1, which investigation showed was
necessary despite the resulting increase in variance (Hammers et al.,
2007).
2.3.2. Manual region of interest delineation
Brainstem regions of interest were deﬁned on a subject-by-
subject basis from their T1-weighted MRI scans by reference to a
human brainstem atlas (Naidich et al., 2009). The ROI masks in-
cluded: medulla – from the top of the dens to the ponto-medullary
sulcus; pons - continuing rostrally above the medulla to the ponto-
mesencephalic sulcus; midbrain - ascending to the inferior border
of the optic tracts; and within the midbrain the PAG corresponding
to the grey matter columns surrounding the aqueduct.
2.3.3. Spatial processing
Spatial processing of the data was performed using statistical
parametric mapping (SPM12, Functional Imaging Laboratory, UCL).
Firstly the two [15O]water scans for each of the two scanning
periods were realigned to each other and subsequently registered
together with the [11C]DPN data to the patient's pre-DBS im-
plantation “planning” T1 MRI data using a rigid body transforma-
tion and a normalised mutual information cost function. For two
subjects these pre-DBS MRI scans were limited to slices of the
target and planned trajectory, which were insufﬁcient for the
study purpose. Therefore, we obtained further MRI images with
the DBS electrode in situ according to the manufacturer's guidance
(“MRI GUIDELINES for Medtronic Deep Brain Stimulation Systems –
2010”).
Spatial normalisation, the registration of the MRI data with an
MNI template, was performed twice. Firstly, a symmetric T1
weighted MNI template image was created using a previously
published approach (Didelot et al., 2010), and the MRI data re-
gistered to this template in order to transform the PET data, in-
cluding estimated parametric maps of kinetic parameters, to this
symmetric 2 mm MNI template using linear interpolation. This
data was subsequently used for voxel-wise statistical analysis
using SPM. Secondly, each patient's MRI data was registered to the
default T1-weighted MNI template with the transformation in-
verse used to transform a region of interest atlas (Hammers et al.,
2003) to each patient using nearest neighbour interpolation. A
grey matter segmented image was then extracted from the MRI
data, smoothed with a 3 mm FWHM Gaussian kernel to degrade it
to the approximate resolution of the PET data and a threshold of
half the full intensity applied in order to reﬁne the atlas regions to
voxels that are predominantly grey matter within each patient.
These regions were subsequently transformed to each PET scanlation of the periaqueductal gray releases endogenous opioids in
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Table 3
Change in POMSSV score with DBS.
POMSSV subset score %change with DBS active P
Anxiety 45.0 0.001
Depression 14.3 0.37
Anger 11.1 0.37
Vigour 20.7 0.30
Fatigue 48.4 0.10
Confusion 46.7 0.08
Total POMSSV 73.6 0.008
POMSSV – Proﬁle of Mood State Shortened Version score (Shacham, 1983). (Two
tailed paired t-test).
H. Sims-Williams et al. / NeuroImage ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 5data, together with manually deﬁned regions for the Medulla,
Pons, Midbrain and PAG, and used to sample all dynamic images of
radioactivity concentrations.
2.3.4. Mapping of DBS electrode position to MNI space
For each subject the position of the DBS lead tip and the po-
sition of the active electrode site was identiﬁed from the planning
MRI scan or repeat MRI scans with the stimulator in situ per-
formed as part of the study. These co-ordinates were transformed
into MNI space using the same individual subject spatial trans-
formations (see Section 2.3.3). These were then projected onto the
MNI space 0.5 mm template as 3 mm spheroids.
2.3.5. SPM voxel-wise statistical analysis
Prior to statistical analysis, parametric images of rCBF, K1 and
VT were smoothed with a 2 mm FWHM Gaussian kernel in order
to minimise the effect of small registration errors and functional
differences between subjects. In addition, images of radioactivity
concentration during the 90 s period postinjection of [15O]water
were smoothed with a 6 mm FWHM Gaussian kernel. In order to
detect any differential effects upon ipsilateral and contralateral
brain regions in response to the unilateral site of PAG stimulation,
two sets of images were included in the analysis, with the second
set created by digitally swapping the left and right hemispheres
for each patient and scan. This enabled statistical analysis of
whether there are any contralateral to ipsilateral differences (la-
teralisation effects). A ﬂexible ﬁxed effects factorial design was
used with a patient main effect (independent) and a side (stimu-
lation or contra-lateral, not independent) stimulation (on or off,
not independent) interaction effect without grand mean scaling
(all) and without intensity normalisation (VT) or using ANCOVA
intensity normalisation (K1, [15O]water data). Contrasts were ex-
amined to compare: stimulation off versus on; lateralisation with
stimulation off and on; and lateralisation with stimulation. A
threshold of po0.001 (uncorrected) was used for the resultant T
maps with a cluster extent threshold of 20 voxels. With respect to
the primary hypothesis a small volume correction was performed
in SPM using a region consisting of the union of the individually
deﬁned subject PAG ROIs transformed into MNI space using
nearest voxel interpolation.
2.3.6. Analysis by region of interest
The mean radioactivity values for the individually deﬁned
brainstem regions of interest and the cerebellum (deﬁned from the
Hammers' atlas (2003)) were calculated to create time activity
curves (TACs) for all [15O]water and [11C]DPN scans. Subsequently
kinetic modelling was employed using the same approach as with
the generation of parametric images in order to derive regional
values for K1, VT and rCBF. Using these regional values we under-
took pairwise comparisons (before and after stimulation) for the
PAG and also nearby regions (pons, medulla and cerebellum) to
see how focal the effects of stimulation were on VT. We also per-
formed correlation analysis of the DBS-induced change in VT
against change in pain VAS (Pearson's correlation) and POMSSV
(see Table 3, using total and subdomain scores with Spearman's
rank correlation).
2.4. Double blind, cross-over trial of acute naloxone administration
Four of our ﬁve study participants were invited back to clinic
for a follow up experiment to see if the beneﬁcial effect of their
DBS stimulation was sensitive to the opiate antagonist naloxone.
One patient (h00635) was excluded because they were maintained
on regular slow release morphine that would confound the in-
terpretation of any naloxone effect. Participants had two testing
sessions (each lasting one hour) in a single day where they hadPlease cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.baseline assessment of spontaneous pain (VAS) and quantitative
sensory testing (QST). The QST was conducted over their painful
area and assayed heat and cold pain threshold (skin temperature
ramped with a thermode from 32 °C at 71.5 °C/s using a Medoc
TSA-II, Israel) and dynamic allodynia (using a cotton bud brushed
at 3 cm s1). Patents were randomised to receive either nalox-
one or saline (placebo) intravenously in a cross-over design. An
incremental bolus dosing schedule was employed to administer a
total of 400 micrograms of naloxone (in aliquots of 50, 100 and 250
micrograms at 3 min intervals) or an equivalent volume of saline
over a 10 min period. Neither the investigator nor the subject
knew the study drug allocation and a priori the dose escalation
would terminate in the event that the patient reported a wor-
sening of their pain of 430%. Immediately after each dose the
patients had repeat VAS and then at regular intervals until 30 min
had elapsed when they had repeat QST. A period of 2 h elapsed
between each limb of the cross-over study.3. Results
3.1. Analgesic action of DBS
We recruited ﬁve patients who had PAG DBS systems
(implanted one to ﬁve years previously) for de-afferentation pain
(see Table 2 and inline supplemental Clinical Vignettes). These
patients all obtained 450% improvement in their pain following
DBS system implantation along with a reduction in their analgesic
medication (inline Supplemental Table 2). Importantly each still
showed an acute “on–off” analgesic response to PAG stimulation
(see Fig. 1A) with a signiﬁcant improvement in mood with sti-
mulation (74% reduction in their Proﬁle of Mood State Shortened
Version score (Shacham, 1983), po0.01, Table 3). In each patient
the stimulation-evoked analgesia was evident within 30 min of
DBS activation (pain VAS decreased by 41% from 5.171.8 to
3.071.2, po0.05) and was maintained for the next two hours. The
analgesic effect of DBS was lost 60 min after DBS withdrawal (pain
VAS increased from 2.570.8 to 4.471.3, po0.05).
3.2. Opioid PET scanning
Based on this DBS proﬁle of action each subject had initial
[11C]DPN and [15O]water PET scans with their DBS off and then
again after switching their DBS on. After reconstruction of the PET
data with kinetic modelling we observed a characteristic pattern
of opioid binding in the brain (Sprenger et al., 2005) (Fig. 1B).
3.3. DBS-evoked changes in opioid binding in the PAG
Brain-wide SPM analysis of VT identiﬁed a single cluster of
reduced [11C]DPN binding with DBS (see Fig. 2A–C, off–on con-
trast). This was located in the dorsal PAG with 31 contiguouslation of the periaqueductal gray releases endogenous opioids in
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Fig. 2. DBS reduces [11C]DPN binding in the PAG. (A–C) Brain-wide statistical parametric mapping (SPM) analysis across all patients showing changes in the total volume of
distribution (VT) on DBS. The SPM analysis shows the T-map (see colour bar) for a single cluster (threshold po0.001 (uncorrected); 20 voxel cluster extent) of 31 voxels
located in the dorsal PAG (p¼0.003 uncorrected) shown superimposed on MNI standard brain (1 mm) in coronal, sagittal and transaxial sections (ipsi – side of DBS). The
inset panels in B show an enlarged image of the cluster and the equivalent sagittal section around the PAG with the superimposed parametric image of the group mean
[11C]DPN VT (DBS off condition) showing that the caudal PAG in the region of the cluster has the highest opioid binding. (D and E) For comparison the position of the DBS lead
active cathode (centre of stimulation contact(s)) mapped into MNI space shown projected onto sagittal and horizontal sections. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
H. Sims-Williams et al. / NeuroImage ∎ (∎∎∎∎) ∎∎∎–∎∎∎6voxels (p¼0.002 after small volume FWE correction with the
composite PAG mask) supporting the primary hypothesis that DBS
reduced [11C]DPN binding through the release of endogenous
opioids (no other clusters were found in this contrast or in the on–
off or lateralised off–on contrasts). This PAG cluster was located at
the caudal pole adjacent to the DBS stimulation electrode sites
(Fig. 2D and E). Analysis of the PAG cluster showed that there was
a fall in VT of 15.5% with DBS (from 45.872.4 to 38.772.5,
po0.005, Fig. 3B). All subjects also showed similar falls in the
whole PAG ROI VT (Fig. 3B, p¼0.06). No signiﬁcant correlation was
found between the DBS-induced reduction [11C]DPN VT in the PAG
cluster and the change in pain score or POMSSV (shown in Fig. 3C
and D, analysis for either absolute or proportionate change in each
variable).3.4. DBS-evoked changes in opioid binding in the brainstem
Given the known anatomical and functional connectivity be-
tween the PAG and the rostral-ventromedial medulla (Fields,
2004; Millan, 2002; Ossipov et al., 2010) (RVM) we performed an
exploratory analysis of the change in [11C]DPN VT in the medulla
and the nearby pons and cerebellum. Although four of ﬁve sub-
jects showed reductions in medullary [11C]DPN VT (group average
reduced by 17%, Fig. 3E) this did not achieve statistical signiﬁcance
(20.672.5 to 17.171.7, p¼0.16, n¼5, two tailed paired t-test). No
signiﬁcant change in [11C]DPN VT was seen in the pons or cere-
bellum emphasising the regional speciﬁcity of the PAG changes
(Fig. 3E).Please cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.3.5. DBS-induced changes in brain blood ﬂow
To test whether the localised change in [11C]DPN VT might be
due to a focal change in blood ﬂow with PAG DBS we performed a
similar SPM analysis for: the K1 parametric maps (reﬂecting the
rate of uptake of [11C]DPN from blood into tissue); for rCBF para-
metric maps; and for radioactivity concentrations during the 90 s
period postinjection of [15O]water, as is commonly done when
conducting activation studies. All of these analyses failed to show
any relative changes in the vicinity of the PAG. This was further
investigated using small volume correction with the PAG mask but
again showed no evidence for localised changes with DBS in any of
the three measures.3.6. Lack of reversal of analgesic effect of DBS by naloxone
Having demonstrated localised changes in opioid binding in the
PAG with DBS, yet without any correlations with the analgesic or
positive effect on mood, we wanted to further test whether this
change in opioid binding was functionally meaningful. To do this
we conducted a double blind, placebo controlled investigation on
four of the ﬁve subjects (one excluded because they were taking
regular opioid analgesia) and examined the effect of systemic
naloxone (400 mcg), an opioid antagonist, on the DBS analgesic
effect. The administration of naloxone to these subjects had no
signiﬁcant effect on ongoing pain scores or on evoked quantitative
sensory test measures including heat and cold pain threshold and
dynamic allodynia (see Fig. 4A and B).lation of the periaqueductal gray releases endogenous opioids in
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Fig. 3. Region of interest analysis of changes in VT [11C]DPN in the brainstem. (A) PAG (yellow), pontine (red) and medullary (green) regions of interest were deﬁned for each
subject allowing extraction of mean [11C]DPN VT. (B) Analysis of the PAG cluster and entire ROI showed a decrease in VT with DBS for every patient that was signiﬁcant at a
group level for the cluster. (C and D) No correlation was found between the change in [11C]DPN VT in the PAG cluster and either the pain NRS or the POMSsv (best ﬁt linear
regression lines shown with conﬁdence intervals overlapping zero). (E) DBS did not produce a signiﬁcant change in medullary, pontine or cerebellar [11C]DPN VT. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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When it was ﬁrst introduced for pain treatment, DBS was be-
lieved to trigger the release of endogenous opioids (Akil et al.,
1976; Hosobuchi et al., 1977) which act upon opioid receptors in
the PAG (Kuhar et al., 1973; Pert and Snyder, 1973) to produce the
analgesic effect but this was subsequently questioned (Duncan
et al., 1991; Young and Chambi, 1987). In this PET imaging study
we show that DBS activation causes a focal reduction in [11C]DPN
VT in the PAG consistent with stimulation-evoked release of
endogenous opioids. As well as having a high density of opioid
receptors the PAG has intrinsic opioid peptide (enkephalin)Please cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.synthesising neurons (Covenas et al., 2004), receives inputs from
opioid containing terminals (see review Carrive, 2012) and opioid
microinjection to the PAG produces potent analgesia (Yaksh and
Rudy, 1978). Our ﬁndings therefore support the principle that DBS
for pain is potentially acting through the endogenous opioid
system.
Previous opioid PET studies have shown a reduction in binding
of the m-opioid radioligand [11C]carfentanil in the PAG during the
application of noxious stimuli to volunteers (Wager et al., 2007;
Zubieta et al., 2005) and also have shown a correlation between
this reduction in [11C]carfentanil binding and the magnitude
of placebo analgesia (Wager et al., 2007). This reduction oflation of the periaqueductal gray releases endogenous opioids in
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Fig. 4. Naloxone does not change ongoing pain ratings or cause hyperalgesia. In a
randomised, double blind, crossover design four of the DBS subjects were given
either naloxone or saline and the effect on spontaneous and evoked pain assessed.
(A) Naloxone did not produce hyperalgesia compared to saline alone. Graph shows
the change in VAS (naloxone – saline) normalised to baseline VAS with positive
values indicating that naloxone produced hyperalgesia (mean 795%CI, One way
rm-ANOVA, ns). (B) Assessment of the change from baselines in heat pain threshold
and dynamic allodynia also showed no signiﬁcant effect of naloxone on either
measure. (lines indicate median values, paired t-test, ns).
H. Sims-Williams et al. / NeuroImage ∎ (∎∎∎∎) ∎∎∎–∎∎∎8radioligand binding was proposed to represent competitive dis-
placement by opioid peptides. Long-term changes in opioid
binding (assayed with [11C]DPN) have also been found in the PAG
in central neuropathic pain (Maarrawi et al., 2007a). The same
group also showed a decrease in opioid binding in neuropathic
pain patients after seven months of chronic motor cortex stimu-
lation (Maarrawi et al., 2007b). DPN is a competitive, non-subtype
selective opioid antagonist that has been used in binding studies
in animal models that have shown it is displaced by opioid peptide
ligands and also in response to activation of the endogenous
opioid system (Neumaier and Chavkin, 1989; Ruiz-Gayo et al.,
1992; Stein et al., 1990). Reduction of DPN binding has been re-
ported in human volunteers after painful stimulation (Sprenger
et al., 2006) and also in patients following reading-induced sei-
zures (Koepp et al., 1998). Although DPN is less speciﬁc for mu
opioid receptors and perhaps less sensitive than Carfentanil in
detecting agonist evoked changes in binding (Quelch et al., 2014)
this appears to have not been a limiting factor in detecting the
DBS-evoked change in [11C]DPN VT. To our knowledge, ours is the
ﬁrst study to use a paired DPN scan design to resolve the acute
reduction in opioid binding (within 90 min) triggered by DBS
supporting the proposition that the reduction in [11C]DPN VT is a
consequence of competitive displacement by endogenous opioid
(as proposed for Carfentanil (Zubieta et al., 2005) and DPN
(Sprenger et al., 2006)).
The purpose of the kinetic modelling was to isolate changes in
radioactivity concentrations due to the altered binding to opioidPlease cite this article as: Sims-Williams, H., et al., Deep brain stimu
humans. NeuroImage (2016), http://dx.doi.org/10.1016/j.neuroimage.receptors (VT) from potential changes due to the radioactivity
within blood and the delivery of this radioactivity to the brain
regions. Despite this, inaccuracies in the model could have pro-
duced residual dependencies. Speciﬁcally, there is the potential for
the regional reduction observed for VT in the PAG to be due to
regional changes in the delivery of the radiotracer (K1) which in
turn is a consequence of regional changes in blood ﬂow (rCBF)
resulting from the electrical stimulation of brain parenchyma. To
examine this we conducted similar voxel-wise statistical testing of
derived [11C]DPN K1 and [15O]water rCBF parametric maps. We
also conducted statistical testing using the radioactivity con-
centration during the 90 s following [15O]water injection which is
commonly used as a surrogate for changes in rCBF. No signiﬁcant
changes were observed in the PAG region in all cases, showing that
the observed changes in VT within the PAG are not a consequence
of any stimulation mediated changes in tracer delivery.
The discrete cluster of opioid displacement was located in a
caudal dorsal/dorso-lateral territory of the PAG (Linnman et al.,
2012) close to the sites of electrical stimulation (which mapped to
the dorso-lateral and lateral areas of the rostral PAG/PVG). In rats
and cats, the PAG is organised into columns from which speciﬁc
patterns of autonomic, sensory and motor co-ordination can be
evoked (Bandler and Shipley, 1994; Carrive, 2012; Lumb, 2002).
Activation of the dorsal/dorso-lateral columns evokes responses
characteristic of ﬁght/ﬂight behaviours with sympatho-activation,
hypertension and a non-opioid mediated analgesia in animals. In
contrast passive coping behaviours are triggered by stimulation of
the ventro-lateral column to trigger hypotension and an opioid-
mediated analgesia. There is supportive evidence from human
studies indicating that DBS of the ventral PAG produces hypoten-
sive actions (Green et al., 2007) and increases vagal tone (Pereira
et al., 2010) whereas stimulation of the dorsal PAG increases blood
pressure (Green et al., 2006). However, another study from the
same team has suggested that changes in local ﬁeld potentials
produced by dorsal PAG stimulation were sensitive to naloxone
(unlike ventral PAG) indicating that this involves opioids (Pereira
et al., 2013). Recent evidence from human MR imaging studies
suggests that a similar columnar organisation is present in man as
seen in rodents (Coulombe et al., 2016; Ezra et al., 2015; Faull et al.,
2015). However, there appear to be cross-species differences in
anatomical connectivity in man particularly for the dorsal PAG that
appears to have good brainstem connectivity consistent with a
potential role in descending control of nociception (Ezra et al.,
2015; Pereira et al., 2010). Our data suggests that the DBS-evoked
opioid displacement was predominantly in the caudal and dorsal
PAG although we acknowledge that the PET imaging methodology
affords limited spatial resolution to discriminate between the re-
latively small columns. We also noted that the cluster was located
over the area with the highest [11C]DPN VT within the PAG sug-
gesting that it has a high density of opioid receptors.
Investigations in animals have shown that the PAG regulates
spinal nociceptive processing via relays in the RVM and in the
pons (locus coeruleus) (Millan, 2002). In the case of the RVM the
PAG is thought to release opioids to disinhibit a descending anti-
nociceptive projection to the spinal cord (Fields, 2004; Heinricher
et al., 2009). Although we found a trend towards reduced [11C]DPN
VT in the medulla (which was of a similar effect size to that seen in
the PAG 15%) this was not signiﬁcant on group analysis. Given
the small numbers of subjects in our study we are cautious about
interpretation of this ﬁnding which will require a larger deﬁnitive
study to resolve.
Although we showed evidence for DBS-evoked release of en-
dogenous opioids we were unable to show any correlation with
the acute improvement in pain or in mood with DBS. Furthermore,
the systemic administration of the opioid antagonist naloxone did
not produce any change in either spontaneous or evoked painlation of the periaqueductal gray releases endogenous opioids in
2016.08.038i
H. Sims-Williams et al. / NeuroImage ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 9measures. This is in agreement with previous blinded DBS studies
that found the analgesic effect of DBS was not blocked completely
by naloxone (Young and Chambi, 1987). Given the small number of
subjects our correlation analysis has limited power and therefore
should be regarded as an exploratory investigation. We were also
relatively cautious in our dosing of naloxone for fear of provoking
uncontrolled pain ﬂares in our patients. We used a dose (400 mcg)
that is clinically recommended for the initial treatment of opioid
overdose and has also been used in similar studies attempting
opioid antagonist reversal of DBS (Hosobuchi et al., 1977; Young
and Chambi, 1987). We estimate that this dose will have blocked
around 30% of the opioid receptors based on previous naloxone
displacement studies of [11C]DPN in man (Melichar et al., 2003).
Although higher doses of naloxone (up to 10 mg) have been ad-
vocated as being necessary in studies of endogenous opioid
mediated mechanisms these were found to be no more effective
than lower doses in the DBS study of Young and Chambi (1987).
Therefore based on the evidence from our study we have been
unable to identify a role for the opioid release in the PAG in the
beneﬁcial analgesic effect of DBS but this may reﬂect insufﬁcient
naloxone dosing to compete with the focal release of high levels of
opioid peptides.
Our pragmatic study design, of necessity, has several limita-
tions because of the challenges of working with this patient po-
pulation with severe pain and the small number of subjects; a
consequence of recruiting from a scarce cohort with implanted
DBS systems for de-afferentation pain, who also had to exhibit a
temporally sharp on–off response to stimulation, and could toler-
ate a long period without stimulation during scanning. Blinding of
the study participants was not feasible as they were aware that
their stimulator had been switched off. However, we think it un-
likely that our ﬁndings represent a placebo effect as the location of
the cluster of voxels was close to the site of stimulation within the
PAG – this would be a remarkably speciﬁc placebo response. Ad-
ditionally, the sequence of the PET scans could not be randomised
to avoid order effects, given the need to study the change in opioid
binding when DBS was activated (and the constraint of a single
arterial cannulation, if at all possible, which meant doing two
scans on a single day). It is worth noting that we found no evi-
dence for order effects as there was no difference in the whole
brain [11C]DPN VT between the two scan sessions and no focal
change in [11C]DPN K1 or rCBF. Notwithstanding these caveats, the
demonstration of changes in opioid binding in the PAG indicates
the sensitivity of the PET methodology and speaks to the magni-
tude of the release of opioid by DBS.
Our study shows that DBS of the PAG causes a focal reduction of
opioid binding in a discrete cluster consistent with the local re-
lease of endogenous opioid peptides. This release is seen in the
dorsal quadrant of the PAG close to the sites of stimulation and in a
region with high opioid binding. It remains to be determined
whether this endogenous opioid release is playing a signiﬁcant
role in the production of analgesia.Acknowledgements
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